On December 7, 2023, a group of health insurers and health insurance administrators filed a class action complaint against Johnson & Johnson and Janssen Biotech, Inc. (collectively “J&J”) in the Eastern District of Virginia...more
1/16/2024
/ Antitrust Litigation ,
Antitrust Provisions ,
Biosimilars ,
Class Action ,
Health Care Providers ,
Health Insurance ,
Johnson & Johnson ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Purple Book ,
Settlement Agreements ,
USPTO